{"id":"W2793957208","doi":"10.1200/jco.2018.36.6_suppl.3","title":"PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC).","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Enzalutamide; Medicine; Prostate cancer; Internal medicine; Clinical endpoint; Oncology; Placebo; Hazard ratio; Gynecology; Randomized controlled trial; Urology; Cancer; Confidence interval; Androgen receptor; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008579202,0.0002715289,0.004196586,0.0003969493,0.00006886723,0.00002296603,0.0001981396,0.0001999229,0.0002410522],"category_scores_gemma":[0.001389799,0.0001439866,0.0004133125,0.0004106638,0.0007890999,0.0001923846,0.00004439476,0.0009361772,0.000006776752],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003424496,"about_ca_system_score_gemma":0.004694982,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004327997,"about_ca_topic_score_gemma":0.002374446,"domain_scores_codex":[0.9930856,0.001252637,0.003961096,0.0003443985,0.0009200266,0.0004362148],"domain_scores_gemma":[0.9926613,0.002711331,0.002653411,0.0002719536,0.001297566,0.0004044216],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9509549,0.01297605,0.0214395,0.00007907414,0.002890697,0.001372596,0.002279411,0.00005081451,0.0007501783,0.00002263167,0.0002934802,0.00689063],"study_design_scores_gemma":[0.9252481,0.06513241,0.004240104,0.0002961658,0.001892088,0.00008444255,0.001531971,0.0004612133,0.0005542262,0.00008071738,0.0003483059,0.0001302113],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877775,0.0008697687,0.00002471334,0.002475456,0.0002804589,0.006623379,0.00001069376,0.000007537529,0.001930465],"genre_scores_gemma":[0.9959574,0.0007741024,0.0008492451,0.0001826473,0.0005587456,0.0004566771,0.000004120877,0.00002983743,0.001187255],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05215636,"threshold_uncertainty_score":0.8328696,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1390578545749188,"score_gpt":0.5135764442932255,"score_spread":0.3745185897183067,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}